UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 177

Sortiert nach

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology, 2019-09, Vol.33 (9), p.1676-1684

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British journal of dermatology (1951), 2015-12, Vol.173 (6), p.1387-1399

2015

Link zum Volltext

Verfügbarkeit prüfen

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.273-286

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.231-241

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.844-852

2018

Link zum Volltext

Verfügbarkeit prüfen

Cannabidiol primer for healthcare professionals

Proceedings - Baylor University. Medical Center, 2020-07, Vol.33 (3), p.376-379

2020

Link zum Volltext

Verfügbarkeit prüfen

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis

Expert opinion on biological therapy, 2021-08, Vol.21 (8), p.983-990

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

Journal of the European Academy of Dermatology and Venereology, 2017-11, Vol.31 (11), p.1867-1875

2017

Link zum Volltext

Verfügbarkeit prüfen

伊赛珠单抗在中度至重度生殖器银屑病中的疗效和安全性

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.e189-e189

2018

Link zum Volltext

Verfügbarkeit prüfen

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

Expert opinion on biological therapy, 2003-04, Vol.3 (2), p.361-370

2003

Link zum Volltext

Verfügbarkeit prüfen

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion

Blood, 1997, Vol.89 (1), p.32-40

1997

Link zum Volltext

Verfügbarkeit prüfen

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2287-2303

2017

Link zum Volltext

Verfügbarkeit prüfen

L’apremilast dans le psoriasis en plaques modéré à sévère : résultats à 32 semaines sur l’atteinte unguéale, palmo-plantaire et du cuir chevelu (ESTEEM 2)

Annales de dermatologie et de vénéréologie, 2015-12, Vol.142 (12), p.S670-S671

2015

Link zum Volltext

Verfügbarkeit prüfen

Ichthyosiform sarcoidosis

Journal of the American Academy of Dermatology, 1999-05, Vol.40 (5), p.862-865

1999

Link zum Volltext

Verfügbarkeit prüfen

Efficacité et tolérance de l’apremilast, inhibiteur oral de la phosphodiestérase 4, dans le psoriasis modéré à sévère (ESTEEM 2) : résultats à 16 semaines d’une étude de phase III

Annales de dermatologie et de vénéréologie, 2014-12, Vol.141 (12), p.S291-S291

2014

Link zum Volltext

Verfügbarkeit prüfen

Update on botulinum toxin for facial aesthetics

Dermatologic clinics, 2002-10, Vol.20 (4), p.749-761

2002

Link zum Volltext

Verfügbarkeit prüfen

EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA

Dermatologic clinics, 2000, Vol.18 (1), p.147-156

2000

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

The Lancet (British edition), 2012-08, Vol.380 (9843), p.738-746

2012

Link zum Volltext

Verfügbarkeit prüfen

Hypertrophic and atrophic scars

Proceedings - Baylor University. Medical Center, 2007-04, Vol.20 (2), p.184-186

2007

Link zum Volltext

Verfügbarkeit prüfen

039 The Development of a Patient Reported Outcome Measure to Assess Sexual Impacts of Genital Psoriasis: GPSIS

Journal of sexual medicine, 2018-02, Vol.15 (2), p.S19-S19

2018

Link zum Volltext

Verfügbarkeit prüfen

Ixekizumab efficacy and safety in moderate‐to‐severe genital psoriasis

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.e177-e177

2018

Link zum Volltext

Verfügbarkeit prüfen

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma

Journal of the American Academy of Dermatology, 1998-11, Vol.39 (5), p.858-863

1998

Link zum Volltext

Verfügbarkeit prüfen

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome

Journal of the American Academy of Dermatology, 1998-02, Vol.38 (2), p.301-305

1998

Link zum Volltext

Verfügbarkeit prüfen

CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY

Dermatologic clinics, 2001, Vol.19 (1), p.119-137

2001

Link zum Volltext

Verfügbarkeit prüfen

A child with nonscarring alopecia

Proceedings - Baylor University. Medical Center, 2005-07, Vol.18 (3), p.269-272

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(154)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

Cannabidiol primer for healthcare professionals

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

伊赛珠单抗在中度至重度生殖器银屑病中的疗效和安全性

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

L’apremilast dans le psoriasis en plaques modéré à sévère : résultats à 32 semaines sur l’atteinte unguéale, palmo-plantaire et du cuir chevelu (ESTEEM 2)

Ichthyosiform sarcoidosis

Efficacité et tolérance de l’apremilast, inhibiteur oral de la phosphodiestérase 4, dans le psoriasis modéré à sévère (ESTEEM 2) : résultats à 16 semaines d’une étude de phase III

Update on botulinum toxin for facial aesthetics

EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Hypertrophic and atrophic scars

039 The Development of a Patient Reported Outcome Measure to Assess Sexual Impacts of Genital Psoriasis: GPSIS

Ixekizumab efficacy and safety in moderate‐to‐severe genital psoriasis

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome

CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY

A child with nonscarring alopecia

Suchergebnisse filtern